

Research Publications

- [1] Merritt E, Sundaralingam M, Cornelius R, and Cleland W. **X-ray crystal and molecular-structure and absolute-configuration of (dihydrogen tripolyphosphato)tetraammincobalt(III) monohydrate, $\text{Co}(\text{NH}_3)_4\text{H}_2\text{P}_3\text{O}_{10}]\text{H}_2\text{O}$ - model for a metal-nucleoside polyphosphate complex.** *Biochemistry*, 17:3274–3278, 1978.
- [2] Merritt E and Sundaralingam M. **Models of metal-nucleoside polyphosphates - structures of unidentate $[\text{CoHP}_2\text{O}_7(\text{NH}_3)_5]\cdot\text{H}_2\text{O}$ [pentaamminepyrophosphatocobalt(III) monohydrate] and bidentate $[\text{CoHP}_2\text{O}_7(\text{NH}_3)_4]\cdot 2\text{H}_2\text{O}$ [tetraamminepyrophosphatocobalt(III) dihydrate].** *Acta Cryst*, B36:2576–2584, 1980.
- [3] Merritt E, Sundaralingam M, and Cornelius R. **Linkage isomerism of a bidentate triphosphate ligand having 6-membered or 8-membered chelate rings.** *J Amer Chem Soc*, 102:6151–6153, 1980.
- [4] Merritt E and Sundaralingam M. **Structure and chelation geometry of alpha,beta,gamma-tridentate triammine(dihydrogentriphosphato)cobalt(iii), $[\text{Co}(\text{NH}_3)_3(\text{H}_2\text{P}_3\text{O}_{10})]$.** *Acta Cryst*, B37:1505–1509, 1981.
- [5] Merritt E, Sundaralingam M, and Dunaway-Mariano D. **Crystal-structure and chelate ring pucker of bidentate (pyrophosphato)tetraaquochromium(III) trihydrate, a model for metal-ADP coordination.** *J Amer Chem Soc*, 103:3565–3567, 1981.
- [6] Merritt E, Sundaralingam M, and Cornelius R. **Structure of alpha,gamma-bidentate tetraammine(dihydrogentriphosphato)cobalt(III) monohydrate.** *Acta Cryst*, B37:657–659, 1981.
- [7] Phizackerley R, Cork C, Merritt E, Hamlin R, Nielsen C, Vernon W, Xuong H, and Perez-Mendez V. **An area detector data acquisition-system for x-ray crystallographic studies of macromolecules and other X-ray-diffraction experiments.** *Nuclear Instruments & Methods in Physics Research*, 195:343, 1982.
- [8] Merritt E and Sundaralingam M. **A method for the determination of furanose ring coordinates in its pseudorotation circuit for different amplitudes of pucker.** *J Biomol Struct Dynamics*, 3:559–578, 1985.
- [9] Phizackerley R, Cork C, and Merritt E. **An area detector data acquisition-system for protein crystallography using multiple-energy anomalous dispersion techniques.** *Nuclear Instruments & Methods in Physics Research*, 246:579–595, 1986.
- [10] Murthy H, Hendrickson W, Orme-Johnson W, Merritt E, and Phizackerley R. **Crystal structure of Clostridium-acidi-urici ferredoxin at 5-A resolution based on measurements of anomalous X-ray-scattering at multiple wavelengths.** *J Biol Chem*, 263:18430–18436, 1988.
- [11] Hendrickson W, Smith J, Phizackerley R, and Merritt E. **Crystallographic structure-analysis of lamprey hemoglobin from anomalous dispersion of synchrotron radiation.** *Proteins-Structure Function and Genetics*, 4:77–88, 1988.
- [12] Guss J, Merritt E, Phizackerley R, Hedman B, Murata M, Hodgson K, and Freeman H. **Phase determination by multiple-wavelength X-ray-diffraction - crystal-structure of a basic blue copper protein from cucumbers.** *Science*, 241:806–811, 1988.
- [13] Hendrickson W, Pahler A, Smith J, Satow Y, Merritt E, and Phizackerley R. **Crystal structure of core streptavidin determined from multiwavelength anomalous diffraction of synchrotron radiation.** *Proc Nat Acad Sci USA*, 86:2190–2194, 1989.

- [14] Kolatkar P, Ernst S, Hackert M, Ogata C, Hendrickson W, Merritt E, and Phizackerley R. **Structure determination and refinement of homotetrameric hemoglobin from *Urechis-caupo* at 2.5 Angstrom resolution.** *Acta Cryst*, B48:191–199, 1992.
- [15] Merritt E, Stout G, Turley S, Sieker L, Jensen L, and Orme-Johnson W. **Structure AT pH 6.5 OF ferredoxin-i from *Azotobacter-vinelandii* at 2.3 Angstrom resolution.** *Acta Cryst*, D49:272–281, 1993.
- [16] Verlinde C, Merritt E, VandenAkker F, Kim H, Feil I, Delboni L, Mande S, Sarfaty S, Petra P, and Hol W. **Protein crystallography and infectious-diseases.** *Protein Science*, 3:1670–1686, 1994.
- [17] Merritt E and Murphy M. **Raster3D Version-2.0 - A program for photorealistic molecular graphics.** *Acta Cryst*, D50:869–873, 1994.
- [18] Merritt E, Sixma T, Kalk K, VanZanten B, and Hol W. **Galactose-binding site in *Escherichia-coli* heat-labile enterotoxin (LT) and cholera-toxin (CT).** *Molec Microbiol*, 13:745–753, 1994.
- [19] Merritt E, Pronk S, Sixma T, Kalk K, VanZanten B, and Hol W. **Structure of partially-activated *Escherichia-coli* heat-labile enterotoxin (LT) at 2.6-Angstrom resolution.** *FEBS Lett*, 337:88–92, 1994.
- [20] Merritt E, Sarfaty S, VandenAkker F, L'hoir C, Martial J, and Hol W. **Crystal structure of cholera-toxin B-pentamer bound to receptor G(M1) pentasaccharide.** *Protein Science*, 3:166–175, 1994.
- [21] VandenAkker F, Merritt E, Pizza M, Domenighini M, Rappuoli R, and Hol W. **The Arg7Lys mutant of heat-labile enterotoxin exhibits great flexibility of active-site loop-47-56 of the A-subunit.** *Biochemistry*, 34:10996–11004, 1995.
- [22] Merritt E, Sarfaty S, Pizza M, Domenighini M, Rappuoli R, and Hol W. **Mutation of a buried residue causes loss of activity but no conformational change in the heat-labile enterotoxin of *Escherichia-coli*.** *Nature Struct Biol*, 2:269–272, 1995.
- [23] Merritt E, Sarfaty S, Chang T, Palmer L, Jobling M, Holmes R, and Hol W. **Surprising leads for a cholera-toxin receptor-binding antagonist - crystallographic studies of CTB mutants.** *Structure*, 3:561–570, 1995.
- [24] Merritt E and Hol W. **AB(5) TOXINS.** *Cur Opin Struct Biol*, 5:165–171, 1995.
- [25] Shoham M, Scherf T, Anglister J, Levitt M, Merritt E, and Hol W. **Structural diversity in a conserved cholera-toxin epitope involved in ganglioside binding.** *Protein Science*, 4:841–848, 1995.
- [26] Guss J, Merritt E, Phizackerley R, and Freeman H. **The structure of a phycocyanin, the basic blue protein from cucumber, refined at 1.8 angstrom resolution.** *J Mol Biol*, 262:686–705, 1996.
- [27] Feil I, Reddy R, deHaan L, Merritt E, vandenAkker F, Storm D, and Hol W. **Protein engineering studies of A-chain loop 47-56 of *Escherichia coli* heat-labile enterotoxin point to a prominent role of this loop for cytotoxicity.** *Molec Microbiol*, 20:823–832, 1996.
- [28] VandenAkker F, Feil I, Roach C, Platas A, Merritt E, and Hol W. **Crystal structure of heat-labile enterotoxin from *Escherichia coli* with increased thermostability introduced by an engineered disulfide bond in the A subunit.** *Protein Science*, 6:2644–2649, 1997.
- [29] Merritt E, Sarfaty S, Feil I, and Hol W. **Structural foundation for the design of receptor antagonists targeting *Escherichia coli* heat-labile enterotoxin.** *Structure*, 5:1485–1499, 1997.
- [30] Merritt E and Bacon D. **Raster3D: Photorealistic molecular graphics.** *Meth Enzymol*, 277:505–524, 1997.

- [31] Merritt E, Sarfaty S, Jobling M, Chang T, Holmes R, Hirst T, and Hol W. **Structural studies of receptor binding by cholera toxin mutants.** *Protein Science*, 6:1516–1528, 1997.
- [32] Feil I, Platas A, van den Akker F, Reddy R, Merritt E, Storm D, and Hol W. **Stepwise transplantation of an active site loop between heat-labile enterotoxins LT-II and LT-I and characterization of the obtained hybrid toxins.** *Protein Engineering*, 11:1103–1109, 1998.
- [33] Merritt E, Kuhn P, Sarfaty S, Erbe J, Holmes R, and Ho W. **The 1.25 angstrom resolution refinement of the cholera toxin B-pentamer: Evidence of peptide backbone strain at the receptor-binding site.** *J Mol Biol*, 282:1043–1059, 1998.
- [34] Minke W, Hovey B, Sarfaty S, Hou Z, Zhang Z, Roach C, Lassila K, Hof S, Hindsgaul O, Holmes R, Fan E, Merritt E, Verlinde C, and Hol W. **Crystal structures of cholera toxin and E-coli heat-labile enterotoxin and structure-based design of toxin antagonists.** *Naunyn-Schmiedebergs Archives of Pharmacology*, 358:SB35, 1998.
- [35] Merritt E. **Comparing anisotropic displacement parameters in protein structures.** *Acta Cryst*, D55:1997–2004, 1999.
- [36] Merritt E. **Expanding the model: anisotropic displacement parameters in protein structure refinement.** *Acta Cryst*, D55:1109–1117, 1999.
- [37] Hovey B, Verlinde C, Merritt E, and Hol W. **Structure-based discovery of a pore-binding ligand: Towards assembly inhibitors for cholera and related AB(5) toxins.** *J Mol Biol*, 285:1169–1178, 1999.
- [38] Fan E, Merritt E, Verlinde C, and Hol W. **AB(5) toxins: structures and inhibitor design.** *Current Opinion in Structural Biology*, 10:680–686, 2000.
- [39] Minke W, Pickens J, Merritt E, Fan E, Verlinde C, and Hol W. **Structure of m-carboxyphenyl-alpha-D-galactopyranoside complexed to heat-labile enterotoxin at 1.3 angstrom resolution: surprising variations in ligand-binding modes.** *Acta Cryst*, D56:795–804, 2000.
- [40] Aman A, Fraser S, Merritt E, Rodighiero C, Kenny M, Ahn M, Hol W, Williams N, Lencer W, and Hirst T. **A mutant cholera toxin B subunit that binds GM1-ganglioside but lacks immunomodulatory or toxic activity.** *Proc Nat Acad Sci USA*, 98:8536–8541, 2001.
- [41] Fan E, Merritt EA, Zhang Z, Pickens JC, Roach C, Ahn M, and Hol WGJ. **Exploration of the GM1 receptor-binding site of heat-labile enterotoxin and cholera toxin by phenyl-ring-containing galactose derivatives.** *Acta Cryst*, D57:201–212, 2001. <http://dx.doi.org/10.1107/S0907444900016814>.
- [42] Zhang Z, Merritt E, Ahn M, Roach C, Hou Z, Verlinde C, Hol W, and Fan E. **Solution and crystallographic studies of branched multivalent ligands that inhibit the receptor-binding of cholera toxin.** *J Amer Chem Soc*, 124:12991–12998, 2002. <http://dx.doi.org/10.1021/ja027584k>.
- [43] Merritt E, Zhang Z, Pickens J, Ahn M, Hol W, and Fan E. **Characterization and crystal structure of a high-affinity pentavalent receptor-binding inhibitor for cholera toxin and E-coli heat-labile enterotoxin.** *J Amer Chem Soc*, 124:8818–8824, 2002. <http://dx.doi.org/10.1021/ja0202560>.
- [44] Pickens J, Merritt E, Ahn M, Verlinde C, Hol W, and Fan E. **Anchor-based design of improved cholera toxin and E-coli heat-labile enterotoxin receptor binding antagonists that display multiple binding modes.** *Chemistry & Biology*, 9:215–224, 2002.
- [45] Hirst T, Fraser S, Soriani M, Aman A, de Haan L, Hearn A, and Merritt E. **New insights into the structure-function relationships and therapeutic applications of cholera-like enterotoxins.** *Int J Med Microbiol*, 291:531–535, 2002.

- [46] Fan E and Merritt EA. **Combating infectious diseases through multivalent design.** *Curr Drug Targets Infect Disord*, 2:161–167, 2002.
- [47] Fan E, O’Neal C, Mitchell D, Robien M, Zhang Z, Pickens J, Tan X, Korotkov K, Roach C, Krumm B, Verlinde C, Merritt E, and Hol W. **Structural biology and structure-based inhibitor design of cholera toxin and heat-labile enterotoxin.** *International Journal of Medical Microbiology*, 294:217–223, 2004. <http://dx.doi.org/10.1016/j.ijmm.2004.07.002>.
- [48] Painter J and Merritt E. **mmLib Python toolkit for manipulating annotated structural models of biological macromolecules.** *J Appl Cryst*, 37:174–178, 2004. <http://dx.doi.org/10.1107/S0021889803025639>.
- [49] Caruthers J, Zucker F, Worthey E, Myler P, Buckner F, Van Voorhuis W, Mehlin C, Boni E, Feist T, Luft J, Gulde S, Lauricella A, Kaluzhniy O, Anderson L, Le Trong I, Holmes M, Earnest T, Soltis M, Hodgson K, Hol W, and Merritt E. **Crystal structures and proposed structural/functional classification of three protozoan proteins from the isochorismatase superfamily.** *Protein Science*, 14:2887–2894, 2005. <http://dx.doi.org/10.1110/ps.051783005>.
- [50] Painter J and Merritt E. **A molecular viewer for the analysis of TLS rigid-body motion in macromolecules.** *Acta Cryst*, D61:465–471, 2005. <http://dx.doi.org/10.1107/S0907444905001897>.
- [51] Painter J and Merritt E. **Optimal description of a protein structure in terms of multiple groups undergoing TLS motion.** *Acta Cryst*, D62:439–450, 2006. <http://dx.doi.org/10.1107/S0907444906005270>.
- [52] Painter J and Merritt E. **TLSMD web server for the generation of multi-group TLS models.** *J Appl Cryst*, 39:109–111, 2006. <http://dx.doi.org/10.1107/S0021889805038987>.
- [53] Holmes M, Buckner F, Van Voorhis W, Verlinde C, Mehlin C, Boni E, DeTitta G, Luft J, Lauricella A, Anderson L, Kalyuzhniy O, Zucker F, Schoenfeld L, Earnest T, Hol W, and Merritt E. **Structure of ribose 5-phosphate isomerase from Plasmodium falciparum.** *Acta Cryst*, F62:427–431, 2006. <http://dx.doi.org/10.1107/S1744309106010876>.
- [54] Hyre D, Le Trong I, Merritt E, Eccleston J, Green N, Stenkamp R, and Stayton P. **Cooperative hydrogen bond interactions in the streptavidin-biotin system.** *Protein Science*, 15:459–467, 2006. <http://dx.doi.org/10.1110/ps.051970306>.
- [55] Arakaki T, Le Trong I, Phizicky E, Quartley E, DeTitta G, Luft J, Lauricella A, Anderson L, Kalyuzhniy O, Worthey E, Myler P, Kim D, Baker D, Hol W, and Merritt E. **Structure of Lmaj006129AAA, a hypothetical protein from Leishmania major.** *Acta Cryst*, F62:175–179, 2006. <http://dx.doi.org/10.1107/S1744309106005902>.
- [56] Holmes M, Buckner F, Van Voorhis W, Mehlin C, Boni E, Earnest T, DeTitta G, Luft J, Lauricella A, Anderson L, Kalyuzhniy O, Zucker F, Schoenfeld L, Hol W, and Merritt E. **Structure of the conserved hypothetical protein MAL13P1.257 from Plasmodium falciparum.** *Acta Cryst*, F62:180–185, 2006. <http://dx.doi.org/10.1107/S1744309106005847>.
- [57] Robien M, Bosch J, Buckner F, Van Voorhis W, Worthey E, Myler P, Mehlin C, Boni E, Kalyuzhniy O, Anderson L, Lauricella A, Gulde S, Luft J, DeTitta G, Caruthers J, Hodgson K, Soltis M, Zucker F, Verlinde C, Merritt E, Schoenfeld L, and Hol W. **Crystal structure of glyceraldehyde-3-phosphate dehydrogenase from Plasmodium falciparum at 2.25 angstrom resolution reveals intriguing extra electron density in the active site.** *Proteins-Structure Function and Bioinformatics*, 62:570–577, 2006. <http://dx.doi.org/10.1002/prot.20801>.

- [58] Bosch J, Robien MA, Mehlin C, Boni E, Riechers A, Buckner FS, Van Voorhis WC, Myler PJ, Worthey EA, DeTitta G, Luft JR, Lauricella A, Gulde S, Anderson LA, Kalyuzhnyi O, Neely HM, Ross J, Earnest TN, Soltis M, Schoenfeld L, Zucker F, Merritt EA, Fan E, Verlinde CLMJ, and Hol WGJ. **Using fragment cocktail crystallography to assist inhibitor design of *Trypanosoma brucei* nucleoside 2-deoxyribosyltransferase.** *J Med Chem*, 49:5939–5946, 2006. <http://dx.doi.org/10.1021/jm060429m>.
- [59] Arakaki T, Neely H, Boni E, Mueller N, Buckner FS, Van Voorhis WC, Lauricella A, DeTitta G, Luft J, Hol WGJ, and Merritt EA. **The structure of *Plasmodium vivax* phosphatidylethanolamine-binding protein suggests a functional motif containing a left-handed helix.** *Acta Cryst*, F63:178–182, 2007. <http://dx.doi.org/10.1107/S1744309107007580>.
- [60] Dantas G, Corrent C, Reichow SL, Havranek JJ, Eletr ZM, Isern NG, Kuhlman B, Varani G, Merritt EA, and Baker D. **High-resolution structural and thermodynamic analysis of extreme stabilization of human procarboxypeptidase by computational protein design.** *J Mol Biol*, 366:1209–1221, 2007. **PMCID 3764424**.
- [61] Flores SC, Keating KS, Painter J, Morcos F, Nguyen K, Merritt EA, Kuhn LA, and Gerstein MB. **HingeMaster: Normal mode hinge prediction approach and integration of complementary predictors.** *Proteins-Structure Function and Bioinformatics*, 73:299–319, 2008. <http://dx.doi.org/10.1002/prot.22060>.
- [62] Larson ET, Deng W, Krumm BE, Napuli A, Mueller N, Van Voorhis WC, Buckner FS, Fan E, Lauricella A, DeTitta G, Luft J, Zucker F, Hol WGJ, Verlinde CLMJ, and Merritt EA. **Structures of substrate- and inhibitor-bound adenosine deaminase from a human malaria parasite show a dramatic conformational change and shed light on drug selectivity.** *J Mol Biol*, 381:975–988, 2008. <http://dx.doi.org/10.1016/j.jmb.2008.06.048>. **PMCID 2600493**.
- [63] Merritt EA, Holmes M, Buckner FS, Van Voorhis WC, Quartly E, Phizicky EM, Lauricella A, Luft J, DeTitta G, Neely H, Zucker F, and Hol WGJ. **Structure of a *Trypanosoma brucei* alpha/beta-hydrolase fold protein with unknown function.** *Acta Cryst*, F64:474–478, 2008. <http://dx.doi.org/10.1107/S174430910801141X>. **PMCID 2496854**.
- [64] Arakaki TL, Buckner FS, Gillespie JR, Malmquist NA, Phillips MA, Kalyuzhnyi O, Luft JR, DeTitta GT, Verlinde CLMJ, Van Voorhis WC, Hol WGJ, and Merritt EA. **Characterization of *Trypanosoma brucei* dihydroorotate dehydrogenase as a possible drug target; structural, kinetic and RNAi studies.** *Molecular Microbiology*, 68:37–50, 2008. <http://dx.doi.org/10.1111/j.1365-2958.2008.06131.x>. **PMCID 2877593**.
- [65] Fan E, Baker D, Fields S, Gelb MH, Buckner FS, Van Voorhis WC, Phizicky E, Dumont M, Mehlin C, Grayhack E, Sullivan M, Verlinde C, DeTitta G, Meldrum DR, Merritt EA, Earnest T, Soltis M, Zucker F, Myler PJ, Schoenfeld L, Kim D, Worthey L, Lacount D, Vignali M, Li J, Mondal S, Massey A, Carroll B, Gulde S, Luft J, Desoto L, Holl M, Caruthers J, Bosch J, Robien M, Arakaki T, Holmes M, Le Trong I, and Hol WG. **Structural genomics of pathogenic protozoa: an overview.** *Methods Mol Biol*, 426:497–513, 2008.
- [66] Verlinde CLMJ, Fan E, Shibata S, Zhang Z, Sun Z, Deng W, Ross J, Kim J, Xiao L, Arakaki TL, Bosch J, Caruthers JM, Larson ET, LeTrong I, Napuli A, Kelley A, Mueller N, Zucker F, Van Voorhis WC, Buckner FS, Merritt EA, and Hol WGJ. **Fragment-Based Cocktail Crystallography by the Medical Structural Genomics of Pathogenic Protozoa Consortium.** *Current Topics in Medicinal Chemistry*, 9:1678–1687, 2009. **PMCID 2897734**.
- [67] Larson ET, Parussini F, Huynh MH, Giebel JD, Kelley AM, Zhang L, Bogyo M, Merritt EA, and Carruthers VB. **Toxoplasma gondii Cathepsin L Is the Primary Target of the Invasion-inhibitory**

- Compound Morpholinurea-leucyl-homophenyl-vinyl Sulfone Phenyl.** *J Biol Chem*, 284:26839–26850, 2009. <http://dx.doi.org/10.1074/jbc.M109.003780>. **PMCID 2785372.**
- [68] Murphy RC, Ojo KK, Larson ET, Castellanos-Gonzalez A, Perera BGK, Keyloun KR, Kim JE, Bhandari JG, Muller NR, Verlinde CLMJ, White Jr. AC, Merritt EA, Van Voorhis WC, and Maly DJ. **Discovery of Potent and Selective Inhibitors of CDPK1 from *C. parvum* and *T. gondii*.** *ACS Med Chem Lett*, 1:331–335, 2010. <http://dx.doi.org/10.1021/ml1000961>. **PMCID 2992447.**
- [69] Zucker F, Champ PC, and Merritt EA. **Validation of crystallographic models containing TLS or other descriptions of anisotropy.** *Acta Cryst*, D66:889–900, 2010. <http://dx.doi.org/10.1107/S0907444910020421>. **PMCID 2917275.**
- [70] Arakaki TL, Carter M, Napuli AJ, Verlinde CLMJ, Fan E, Zucker F, Buckner FS, Van Voorhis WC, Hol WGJ, and Merritt EA. **The structure of tryptophanyl-tRNA synthetase from *Giardia lamblia* reveals divergence from eukaryotic homologs.** *J Struct Biol*, 171:238–243, 2010. <http://dx.doi.org/10.1016/j.jsb.2010.04.010>. **PMCID 2885457.**
- [71] Zucker FH, Stewart C, dela Rosa J, Kim J, Zhang L, Xiao L, Ross J, Napuli AJ, Mueller N, Castaneda LJ, Hewitt SRN, Arakaki TL, Larson ET, Subramanian E, Verlinde CLMJ, Fan E, Buckner FS, Van Voorhis WC, Merritt EA, and Hol WGJ. **Prediction of protein crystallization outcome using a hybrid method.** *J Struct Biol*, 171:64–73, 2010. <http://dx.doi.org/10.1016/j.jsb.2010.03.016>. **PMCID 2957526.**
- [72] Ojo KK, Larson ET, Keyloun KR, Castaneda LJ, DeRocher AE, Inampudi KK, Kim JE, Arakaki TL, Murphy RC, Zhang L, Napuli AJ, Maly DJ, Verlinde CLMJ, Buckner FS, Parsons M, Hol WGJ, Merritt EA, and Van Voorhis WC. **Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors.** *Nature Struct Mol Biol*, 17:602–607, 2010. <http://dx.doi.org/10.1038/nsmb.1818>. **PMCID 2896873.**
- [73] Behnke CA, Le Trong I, Godden JW, Merritt EA, Teller DC, Bajorath J, and Stenkamp RE. **Atomic resolution studies of carbonic anhydrase II.** *Acta Cryst*, D66:616–627, 2010. <http://dx.doi.org/10.1107/S0907444910006554>. **PMCID 2865367.**
- [74] Merritt EA, Arakaki TL, Gillespie JR, Larson ET, Kelley A, Mueller N, Napuli AJ, Kim J, Zhang L, Verlinde CLMJ, Fan E, Zucker F, Buckner FS, Van Voorhis WC, and Hol WGJ. **Crystal Structures of Trypanosomal Histidyl-tRNA Synthetase Illuminate Differences between Eukaryotic and Prokaryotic Homologs.** *J Mol Biol*, 397:481–494, 2010. <http://dx.doi.org/10.1016/j.jmb.2010.01.051>. **PMCID 2834879.**
- [75] Larson ET, Mudeppa DG, Gillespie JR, Mueller N, Napuli AJ, Arif JA, Ross J, Arakaki TL, Lauricella A, DeTitta G, Luft J, Zucker F, Verlinde CLMJ, Fan E, Van Voorhis WC, Buckner FS, Rathod PK, Hol WGJ, and Merritt EA. **The Crystal Structure and Activity of a Putative Trypanosomal Nucleoside Phosphorylase Reveal It to be a Homodimeric Uridine Phosphorylase.** *J Mol Biol*, 396:1244–1259, 2010. <http://dx.doi.org/10.1016/j.jmb.2010.01.013>. **PMCID 2844865.**
- [76] Merritt EA, Arakaki TL, Larson ET, Kelley A, Mueller N, Napuli AJ, Zhang L, DeDitta G, Luft J, Verlinde CLMJ, Fan E, Zucker F, Buckner FS, Van Voorhis WC, and Hol WGJ. **Crystal structure of the aspartyl-tRNA synthetase from *Entamoeba histolytica*.** *Mol Biochem Parasitology*, 169:95–100, 2010. <http://dx.doi.org/10.1016/j.molbiopara.2009.10.005>. **PMCID 2791181.**
- [77] Larson ET, Kim JE, Zucker FH, Kelley A, Mueller N, Napuli AJ, Verlinde CLMJ, Fan E, Buckner FS, Van Voorhis WC, Merritt EA, and Hol WGJ. **Structure of *Leishmania major* methionyl-tRNA synthetase in complex with intermediate products methionyladenylate and pyrophosphate.** *Biochimie*, 93:570–582, 2011. <http://dx.doi.org/10.1016/j.biochi.2010.11.015>. **PMCID 3039092.**

- [78] Larson ET, Kim JE, Castaneda LJ, Napuli AJ, Zhang Z, Fan E, Zucker FH, Verlinde CL, Buckner FS, Voorhis WCV, Hol WG, and Merritt EA. **The double-length tyrosyl-trna synthetase from the eukaryote leishmania major forms an intrinsically asymmetric pseudo-dimer.** *J Mol Biol*, 409:159–176, 2011. <http://dx.doi.org/DOI: 10.1016/j.jmb.2011.03.026>. **PMCID 3095712**.
- [79] Ojo KK, Arakaki TL, Napuli AJ, Inampudi KK, Keyloun KR, Zhang L, Hol WGJ, Verlinde CLMJ, Merritt EA, and Van Voorhis WC. **Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3.** *Molecular and Biochemical Parasitology*, 176:98–108, 2011. <http://dx.doi.org/10.1016/j.molbiopara.2010.12.009>. **PMCID 3045540**.
- [80] Shibata S, Gillespie JR, Kelley AM, Napuli AJ, Zhang Z, Kovzun KV, Pefley RM, Lam J, Zucker FH, Van Voorhis WC, Merritt EA, Hol WGJ, Verlinde CLMJ, Fan E, and Buckner FS. **Selective Inhibitors of Methionyl-tRNA Synthetase Have Potent Activity against Trypanosoma brucei Infection in Mice.** *Antimicrobial Agents and Chemotherapy*, 55:1982–1989, 2011. <http://dx.doi.org/10.1128/AAC.01796-10>. **PMCID 3088252**.
- [81] Shibata S, Zhang Z, Korotkov KV, Delatosa J, Napuli AJ, Kelley AM, Mueller N, Ross J, Zucker FH, Buckner FS, Merritt EA, Verlinde CLMJ, Van Voorhis WC, Hol WGJ, and Fan E. **Screening a fragment cocktail library using ultrafiltration.** *Analytical and Bioanalytical Chemistry*, 401:1585–1591, 2011. <http://dx.doi.org/10.1007/s00216-011-5225-7>. **PMCID 3166647**.
- [82] Merritt EA, Arakaki TL, Gillespie R, Napuli AJ, Kim JE, Buckner FS, Van Voorhis WC, Verlinde CLMJ, Fan E, Zucker F, and Hol WGJ. **Crystal structures of three protozoan homologs of tryptophanyl-tRNA synthetase.** *Molecular and Biochemical Parasitology*, 177:20–28, 2011. <http://dx.doi.org/10.1016/j.molbiopara.2011.01.003>. **PMCID 3066001**.
- [83] Merritt EA. **Some B_{eq} are more equivalent than others.** *Acta Cryst*, A67:512–516, 2011. <http://dx.doi.org/10.1107/S0108767311034350>. **PMCID 3211245**.
- [84] Merritt EA. **To B or not to B - a question of resolution?** *Acta Cryst*, D68:468–477, 2012. **PMCID 3322606**.
- [85] Johnson SM, Murphy RC, Geiger JA, DeRocher AE, Zhang Z, Ojo KK, Larson ET, Perera BGK, Dale EJ, He P, Reid MC, Fox AMW, Mueller NR, Merritt EA, Fan E, Parsons M, Voorhis WCV, and Maly DJ. **Development of toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity.** *J Med Chem*, 55:2416–2426, 2012. **PMCID 3306180**.
- [86] Larson ET, Ojo KK, Murphy RC, Johnson SM, Zhang Z, Kim JE, Leibly DJ, Fox AMW, Reid MC, Dale EJ, Perera BGK, Kim J, Hewitt SN, Hol WGJ, Verlinde CLMJ, Fan E, Voorhis WCV, Maly DJ, and Merritt EA. **Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.** *J Med Chem*, 55:2803–2810, 2012. **PMCID 3336864**.
- [87] Zucker FH, Kim HY, and Merritt EA. **PROSPERO: online prediction of crystallographic success from experimental results and sequence.** *J Appl Cryst*, 45:598–602, 2012. **PMCID 3359727**.
- [88] Ojo KK, Pfander C, Mueller NR, Burstroem C, Larson ET, Bryan CM, Fox AM, Reid MC, Johnson SM, Murphy RC, Kennedy M, Mann H, Leibly DJ, Hewitt SN, Verlinde CL, Kappe S, Merritt EA, Maly DJ, Billker O, and Voorhis WCV. **Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors.** *Journal of Clinical Investigation*, 122:2301–2305, 2012. **PMCID 3366411**.
- [89] Zhang Z, Ojo KK, Johnson SM, Larson ET, He P, Geiger JA, Castellanos-Gonzalez A, White AC, Jr., Parsons M, Merritt EA, Maly DJ, Verlinde CLMJ, Voorhis WCV, and Fan E. **Benzoylbenzimidazole-based selective inhibitors targeting cryptosporidium parvum and toxoplasma gondii calcium-dependent protein kinase-1.** *Bioorganic & Medicinal Chemistry Letters*, 22:5264–5267, 2012. **PMCID 3420979**.

- [90] Larson ET, Kim JE, Napuli AJ, Verlinde CL, Fan E, Zucker FH, Voorhis WCV, Buckner FS, Hol WG, and Merritt EA. **Crystal structure of the prolyl-tRNA synthetase from the eukaryotic pathogen *Giardia lamblia*.** *Acta Cryst*, D68:1194–1200, 2012. **PMCID 3489102.**
- [91] Ranjitkar P, Perera BGK, Swaney D, Hari SB, Larson ET, Krishnamurty R, Merritt EA, Villén J, and Maly DJ. **Affinity-based probes based on type II kinase inhibitors.** *J Amer Chem Soc*, 134:19017–19025, 2012. **PMCID 3523701.**
- [92] Krishnamurty R, Brigham JL, Leonard SE, Ranjitkar P, Larson ET, Dale EJ, Merritt EA, and Maly DJ. **Active site profiling reveals coupling between domains in src-family kinases.** *Nature Chem Biol*, 9:43–50, 2013. **PMCID 3522794.**
- [93] Hari SB, Merritt EA, and Maly DJ. **Sequence determinants of a specific inactive protein kinase conformation.** *Chem Biol*, 20:806–815, 2013. **PMCID 3742363.**
- [94] Ojo KK, Merritt EA, Maly DJ, and Voorhis WCV. **Calcium-dependent protein kinases of apicomplexan parasites as drug targets.** In C Doerig, G Spaeth, and M Wiese, editors, *Protein Phosphorylation in Parasites*. Wiley-Blackwell, 2013.
- [95] Zhang Z, Ojo KK, Vidadala R, Huang W, Geiger JA, Scheele S, Choi R, Reid MC, Keyloun KR, Rivas K, Siddaramaiah LK, Comess KM, Robinson KP, Merta PJ, Kifle L, Hol WGJ, Parsons M, Merritt EA, Maly DJ, Verlinde CLMJ, Voorhis WCV, and Fan E. **Potent and selective inhibitors of CDPK1 from *T. gondii* and *C. parvum* based on a 5-aminopyrazole-4-carboxamide scaffold.** *ACS Med Chem Lett*, 5:40–44, 2014. <http://dx.doi.org/dx.doi.org/10.1021/ml400315s>. **PMCID 3908674.**
- [96] Vidadala RSR, Ojo KK, Johnson SM, Zhang Z, Leonard SE, Mitra A, Choi R, Reid MC, Keyloun KR, Fox AM, Kennedy M, Silver-Brace T, Hume JC, Kappe S, Verlinde CL, Fan E, Merritt EA, Voorhis WCV, and Maly DJ. **Development of potent and selective plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes.** *Eur J Med Chem*, 74:562–573, 2014. <http://dx.doi.org/dx.doi.org/10.1016/j.ejmech.2013.12.048>. **PMCID 4024383.**
- [97] Hari SB, Merritt EA, and Maly DJ. **Conformation-selective ATP-competitive inhibitors control regulatory interactions and noncatalytic functions of mitogen-activated protein kinases.** *Chem Biol*, 21:628–635, 2014. <http://dx.doi.org/dx.doi.org/10.1016/j.chembiol.2014.02.016>. **PMCID 4123212.**
- [98] Ojo KK, Reid MC, Siddaramaiah LK, Müller J, Winzer P, Zhang Z, Keyloun KR, Vidadala RSR, Merritt EA, Hol WGJ, Maly DJ, Fan E, and Voorhis WCV. **Neospora caninum calcium-dependent protein kinase 1 is an effective drug target for neosporosis therapy.** *PLOS One*, 9:e92929, 2014. <http://dx.doi.org/dx.doi.org/10.1371/journal.pone.0092929>. **PMCID 3969379.**
- [99] Keyloun KR, Reid MC, Choi R, Song Y, Fox AM, Hillesland HK, Zhang Z, Vidadala R, Merritt EA, Lau AO, Maly DJ, Fan E, Barrett LK, Van Voorhis WC, and Ojo KK. **The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites.** *Parasitology*, 141:1499–1509, 2014. **PMCID 4390295.**
- [100] Huang W, Ojo KK, Zhang Z, Rivas K, Vidadala RSR, Scheele S, DeRocher AE, Choi R, Hulverson MA, Barrett LK, Bruzual I, Siddaramaiah LK, Kerchner KM, Kurnick MD, Freiberg GM, Kempf D, Hol WG, Merritt EA, Neckermann G, de Hostos EL, Isoherranen N, Maly DJ, Parsons M, Doggett JS, Voorhis WCV, and Fan E. **SAR studies of 5-aminopyrazole-4-carboxamide analogs as potent and selective inhibitors of *Toxoplasma gondii* CDPK1.** *ACS Med Chem Lett*, 6:1184–1189, 2015. **PMCID 4677665.**

- [101] Vidadala RS, Rivas KL, Ojo KK, Hulverson MA, Zambriski JA, Bruzual I, Schultz TL, Huang W, Zhang Z, Scheele S, DeRocher AE, Choi R, Barrett LK, Siddaramaiah LK, Hol WG, Fan E, Merritt EA, Parsons M, Freiberg G, Marsh K, Kempf DJ, Carruthers VB, Isoherranen N, Doggett JS, Van Voorhis WC, and Maly DJ. **Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.** *J Med Chem*, 59:6531–6546, 2016. <http://dx.doi.org/10.1021/acs.jmedchem.6b00760>. PMID 5100899.
- [102] Hennessey KM, Smith TR, Xu JW, Alas GCM, Ojo KK, Merritt EA, and Paredez AR. **Identification and validation of small-gatekeeper kinases as drug targets in giardia lamblia.** *PLOS Neglected Tropical Diseases*, 10:1–20, 2016. <http://dx.doi.org/10.1371/journal.pntd.0005107>. PMID 5091913.
- [103] Van Voorhis WC, Dogget JS, Parsons M, Hulverson MA, Choi R, Arnold S, Riggs MW, Hemphill A, Howe DK, Mealey R, Lau AOT, Merritt EA, Maly DJ, Fan E, and Ojo KK. **Extended-spectrum antiprotozoal bumped kinase inhibitors: A review.** *ExperParasitol*, 2017. PMID 5498274.
- [104] Vidadala RSR, Golkowski M, Hulverson MA, Choi R, McCloskey MC, Whitman GR, Huang W, Arnold SLM, Barrett LK, Fan E, Merritt EA, Van Voorhis WC, Ojo KK, and Maly DJ. **7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4- d]pyrimidin-4-amine-Based Inhibitors.** *ACS Infectious Diseases*, 4:516–522, 2018. <http://dx.doi.org/10.1021/acsinfecdis.7b00224>. PMID: 29522315.
- [105] Scheele S, Geiger JA, DeRocher AE, Choi R, Smith TR, Hulverson MA, Vidadala RSR, Maly LKBDJ, Merritt EA, Ojo KK, Voorhis WCV, and Parsons M. **Toxoplasma calcium-dependent protein kinase 1 inhibitors: probing activity and resistance using cellular thermal shift assays.** *Antimicrob Agents Chemother*, 62:e00051–18, 2018. PMID 5971589.
- [106] Hennessey KM, Rogiers IC, Shih HW, Hulverson MA, Choi R, McCloskey MC, Whitman GR, Barrett LK, Merritt EA, Paredez AR, and Ojo KK. **Screening of the pathogen box for inhibitors with dual efficacy against giardia lamblia and cryptosporidium parvum.** *PLOS Neglected Tropical Diseases*, 12:1–16, 2018. <http://dx.doi.org/10.1371/journal.pntd.0006673>. PMID 6095626.
- [107] Ahler E, Register AC, Chakraborty S, Fang L, Dieter EM, Sitko KA, Vidadala RSR, Trevillian BM, Golkowski M, Gelman H, Stephany JJ, Rubin AF, Merritt EA, Fowler DM, and Maly DJ. **A combined approach reveals a regulatory mechanism coupling src’s kinase activity, localization, and phosphotransferase-independent functions.** *Molecular Cell*, 74:393 – 408.e20, 2019. <http://dx.doi.org/https://doi.org/10.1016/j.molcel.2019.02.003>. PMID 6474823.
- [108] Michaels SA, Shih HW, Zhang B, Navaluna ED, Zhang Z, Ranade RM, Gillespie JR, Merritt EA, Fan E, Buckner FS, Paredez AR, and Ojo KK. **Methionyl-tRNA synthetase inhibitor has potent in vivo activity in a novel Giardia lamblia luciferase murine infection model.** *J Antimicrob Chemother*, 2020. <http://dx.doi.org/10.1093/jac/dkz567>.
- [109] Hennessey KM, Alas GCM, Rogiers I, Li R, Merritt EA, and Paredez AR. **Nek8445, a protein kinase required for microtubule regulation and cytokinesis in giardia lamblia.** *Mol Biol Cell*, 31:1611–1622, 2020.